0.7771
price up icon2.18%   0.0166
after-market アフターアワーズ: .80 0.0229 +2.95%
loading
前日終値:
$0.7605
開ける:
$0.752
24時間の取引高:
691.07K
Relative Volume:
1.07
時価総額:
$100.38M
収益:
-
当期純損益:
$-26.91M
株価収益率:
-3.5323
EPS:
-0.22
ネットキャッシュフロー:
$-19.57M
1週間 パフォーマンス:
-6.56%
1か月 パフォーマンス:
-13.45%
6か月 パフォーマンス:
-40.22%
1年 パフォーマンス:
-40.22%
1日の値動き範囲:
Value
$0.7302
$0.797
1週間の範囲:
Value
$0.7302
$0.859
52週間の値動き範囲:
Value
$0.5526
$1.66

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
名前
Atossa Therapeutics Inc
Name
セクター
Healthcare (1170)
Name
電話
206.588.0256
Name
住所
10202 5TH AVENUE NE, SEATTLE, WA
Name
職員
13
Name
Twitter
@atossainc
Name
次回の収益日
2025-03-25
Name
最新のSEC提出書
Name
ATOS's Discussions on Twitter

ATOS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.7771 107.43M 0 -26.91M -19.57M -0.22
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2018-01-26 開始されました Maxim Group Buy

Atossa Therapeutics Inc (ATOS) 最新ニュース

pulisher
07:08 AM

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World

07:08 AM
pulisher
May 28, 2025

Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 28, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire

May 22, 2025
pulisher
May 20, 2025

Atossa Therapeutics announces issuance of U.S. patent - MSN

May 20, 2025
pulisher
May 20, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan

May 20, 2025
pulisher
May 18, 2025

HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World

May 18, 2025
pulisher
May 15, 2025

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 14, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit

May 13, 2025
pulisher
May 13, 2025

ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 13, 2025
pulisher
May 10, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

May 08, 2025
pulisher
May 05, 2025

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com

May 05, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 03, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus

May 02, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News

May 02, 2025
pulisher
May 02, 2025

LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 02, 2025
pulisher
May 01, 2025

Atossa Therapeutics Inc (ATOS)’s results reveal risk - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Inc (ATOS) rating initates by Maxim Group - knoxdaily.com

Apr 30, 2025
pulisher
Apr 30, 2025

Sector Update: Health Care - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics (ATOS) Secures Patent for Key Breast Cancer Drug Formulations - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa stock gains on U.S. patent win (ATOS:NASDAQ) - Seeking Alpha

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Inc (ATOS) Stock: Navigating a Year of Volatility - investchronicle.com

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281 - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics (ATOS) Secures Patent for Innovative Drug Fo - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics secures new patent for breast cancer drug By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - The Manila Times

Apr 30, 2025
pulisher
Apr 30, 2025

Atossa Therapeutics secures new patent for breast cancer drug - Investing.com Australia

Apr 30, 2025
pulisher
Apr 30, 2025

Major Patent Breakthrough: Atossa's Cancer Drug Portfolio Expands with 58 New Protected Formulations - Stock Titan

Apr 30, 2025
pulisher
Apr 29, 2025

Atossa Therapeutics Proposes Potentially Groundbreaking Study Ai - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Atossa Therapeutics (ATOS) Launches SMART 2.0 Phase 3 Clinical S - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Revolutionary Breast Cancer Prevention Trial Could Reduce Risk by 20% in High-Risk Women - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

Hilton (NYSE:HLT) Reports Sales Below Analyst Estimates In Q1 Earnings - The Globe and Mail

Apr 29, 2025
pulisher
Apr 29, 2025

Renaissance Technologies LLC Boosts Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Apr 29, 2025

Atossa Therapeutics Inc (ATOS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Atossa Therapeutics Inc (ATOS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Remmel H. Lawrence
Director
Mar 26 '25
Buy
0.70
10,000
7,000
10,257
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):